Loading...
Loading...
Browse all stories on DeepNewz
VisitWill Viridian Therapeutics' stock price increase by more than 50% by the end of 2024?
Yes • 50%
No • 50%
Stock market data from financial platforms like Yahoo Finance or Bloomberg
Viridian Therapeutics Announces Positive Results from Phase 3 THRIVE Trial for TED with VRDN-001 Veligrotug
Sep 10, 2024, 11:06 AM
Viridian Therapeutics announced positive topline results from its Phase 3 THRIVE clinical trial of Veligrotug (VRDN-001), an experimental treatment for thyroid eye disease (TED). The results showed significant improvement in reducing eye bulging and achieving primary goals. Key findings include a 70% proptosis responder rate, 54% complete resolution of diplopia, and 64% reduction of Clinical Activity Score to 0 or 1. The treatment was well-tolerated with no treatment-related serious adverse events. Viridian plans to submit a Biologics License Application (BLA) in 2025. The results compared favorably to a similar drug already approved and sold by Amgen. A webcast to discuss the results is scheduled for September 10, 2024, at 8:00am ET.
View original story
Yes • 50%
No • 50%
60% - 70% • 25%
Less than 50% • 25%
More than 70% • 25%
50% - 60% • 25%
Above $40 • 25%
$30 - $40 • 25%
Below $20 • 25%
$20 - $30 • 25%